Larimar Therapeutics, Inc. (LRMR:NASDAQ) closed at $2.42 on October 21, 2026, down 0.82% on the day. The stock trades 62.3% below its 52-week high of $6.42 and 26.4% above its 52-week low of $1.92. Over the past year, it lost 38.4%. Larimar Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, LRMR closed higher on 112 days (44%). Its best day was February 25, 2026 (+61.25%) and its worst was November 5, 2025 (-15.26%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 2 times.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Find more stocks like LRMR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.